Non-pneumonitis immune-mediated adverse events (imAEs) with durvalumab in patients with unresectable stage III NSCLC (PACIFIC).
Date
2020Author
Antonia, Scott Joseph
Quantin, Xavier
Hui, Rina
Ozguroglu, Mustafa
Murakami, Shuji
Broadhurst, Helen
Newton, Michael
Dennis, Phillip A.
Naidoo, Jarushka
Vansteenkiste, Johan F.
Faivre-Finn, Corinne
Metadata
Show full item recordCollections
- Makale [92796]